Linked Data API

Show Search Form

Search Results

1134019
registered interest false more like this
date less than 2019-06-24more like thismore than 2019-06-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how products selected by the Accelerated Access Collaborative will be funded. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 268507 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>As announced in the Life Sciences Sector Deal 2, up to £2 million of Pathway Transformation Funding has been made available to support the use and integration of product selected by the Accelerated Access Collaborative (AAC) into every day practice within the National Health Service. In addition, four of the seven technology areas currently receiving AAC support have been selected to be funded by NHS England through the Innovation and Technology Payment programme (ITP). The ITP aims to remove financial and procurement barriers to support the NHS to adopt innovative medical devices, diagnostics, and digital products.</p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-02T16:07:33.677Zmore like thismore than 2019-07-02T16:07:33.677Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1134020
registered interest false more like this
date less than 2019-06-24more like thismore than 2019-06-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether all products considered by the Accelerated Access Collaborative will have to be cost-neutral to the NHS. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 268508 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>As it continues to drive forward the assessment and uptake of the best products for support, the Accelerated Access Collaborative (AAC) has been empowered to be flexible and pragmatic enough to identify truly game-changing innovations, that may not be cost-neutral in year, but are assessed by the National Institute for Health and Care Excellence to be both clinically and cost-effective. This will allow the AAC to identify products, or classes of products, that are most likely to significantly transform care in the National Health Service.</p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-02T16:06:04.58Zmore like thismore than 2019-07-02T16:06:04.58Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1134022
registered interest false more like this
date less than 2019-06-24more like thismore than 2019-06-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how the Accelerated Access Collaborative plans to balance its focus on (a) medicines, (b) diagnostic tools and (c) digital services. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 268510 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>There are no restrictions on the type of innovation that can be supported by the Accelerated Access Collaborative (AAC). Medicinal products, therapeutic technologies, devices, diagnostics, and digital technologies are eligible to receive support.</p><p>In October 2018, the AAC announced it was supporting to increased uptake and use of 12 high performing products, which span seven technology areas, in the National Health Service. Of the seven categories selected for support, two are medicines, four are diagnostic tests, and one is a device.</p><p>Further information about the products the AAC are supporting can be found at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-02T16:06:55.223Zmore like thismore than 2019-07-02T16:06:55.223Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1132910
registered interest false more like this
date less than 2019-06-18more like thismore than 2019-06-18
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Dementia: Diagnosis more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps he is taking to increase the accuracy of dementia diagnoses. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 266210 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-26more like thismore than 2019-06-26
answer text <p>The Challenge on Dementia 2020 sets out the ambition for two thirds of people with dementia to receive a formal diagnosis. This has been achieved and exceeded nationally. Our focus now is on reducing the variation in local diagnosis rates and NHS England has published guidance and put programmes in place to further improve the quality and timeliness of diagnosis across the country.</p><p>For example, the ‘Implementation guide and resource pack for dementia care’ published in July 2017 sets out key recommendations on how services should be configured to provide good-quality diagnosis and post-diagnostic care for people with dementia and their carers. It includes key roles and activity in primary care and memory assessment services to facilitate an accurate and timely diagnosis of dementia, while ensuring access to appropriate support following diagnosis. The resource pack is available at the following link:</p><p><a href="https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/" target="_blank">https://www.england.nhs.uk/mental-health/dementia/implementation-guide-and-resource-pack-for-dementia-care/</a></p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-06-26T14:40:04.677Zmore like thismore than 2019-06-26T14:40:04.677Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1129344
registered interest false more like this
date less than 2019-06-03more like thismore than 2019-06-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Dietetics: Recruitment more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what plans he has to increase the numbers of dietitians in the NHS and social care to support the NHS Long Term Plan priorities of tackling frailty in old age, obesity and type 2 diabetes and improving health outcomes within stroke, cancer and dementia care. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 259223 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-11more like thismore than 2019-06-11
answer text <p>The National Health Service published its interim People Plan on 3 June. It sets out a plan of action to meet the health requirements of the population outlined in the NHS Long Term Plan. The interim People Plan puts NHS people at the heart of NHS policy. The development of the dietetic workforce was central to the allied health professionals workforce programme for the plan and was developed by engaging widely with staff, patients, employers, professional organisations, regulatory bodies, voluntary sector, academia and other experts. We expect the final People Plan to be published within two months of the Spending Review.</p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-06-11T14:53:21.96Zmore like thismore than 2019-06-11T14:53:21.96Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1105315
registered interest false more like this
date less than 2019-03-26more like thismore than 2019-03-26
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cervical Cancer: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of people being able to self-refer for a smear test in a local sexual health clinic. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 237191 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>The United Kingdom National Screening Committee has made no assessment of the evidence to offer self-referral as part of the National Health Service cervical screening programme. The programme is working with contraception and sexual health clinics to support women who attend for their routine cervical screening, which is offered by some local authorities.</p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-04-02T15:40:52.38Zmore like thismore than 2019-04-02T15:40:52.38Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104692
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many oncology patients have been registered to receive treatment through the NHS in each year since 2010. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 236365 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
grouped question UIN
236367 more like this
236369 more like this
question first answered
less than 2019-04-02T11:24:26.92Zmore like thismore than 2019-04-02T11:24:26.92Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104693
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Health Professions more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many (a) nurses and (b) doctors are specifically employed within the oncology speciality. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 236366 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS Digital publishes Hospital and Community Health Services workforce statistics. These include staff working in hospital trusts and clinical commissioning groups, but not staff working in primary care, local authorities or other providers.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 1,317 doctors with a speciality in clinical oncology and 985 doctors with a speciality in medical oncology. The figures include all doctors working in the specialty of oncology such as consultants, associate specialists, specialty doctors, doctors in training etc.</p><p> </p><p>The latest NHS Digital workforce statistics show that as at 30 December 2018 there are 2,093 nurses who work in an area of ‘clinical oncology’ and 1,237 nurses who work in an area of ‘medical oncology’. This data represents nurses who are working in services related to oncology, rather than nurses with specialist training in oncology.</p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-04-02T11:43:26.817Zmore like thismore than 2019-04-02T11:43:26.817Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104694
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how much the NHS spent on providing oncological treatment in each year since 2010. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 236367 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
grouped question UIN
236365 more like this
236369 more like this
question first answered
less than 2019-04-02T11:24:27Zmore like thismore than 2019-04-02T11:24:27Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this
1104696
registered interest false more like this
date less than 2019-03-25more like thismore than 2019-03-25
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, how many IT systems are used within oncological treatment in the NHS. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 236369 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-04-02more like thismore than 2019-04-02
answer text <p>NHS England holds data in relation to the number of people starting definitive cancer treatment in each year from 2010. This includes people who have received their first cancer treatment in that year, which includes all types of cancer treatment and not just oncological treatments (chemotherapy and radiotherapy).</p><p> </p><p>The number of people receiving their first treatment for cancer each year has risen significantly each year since 2010. It should be noted that the 2018 data is published but includes three months of provisional data, so could be subject to slight adjustment.</p><table><tbody><tr><td><p>Year</p></td><td><p>Patients receiving first treatment</p></td></tr><tr><td><p>2010</p></td><td><p>242,396</p></td></tr><tr><td><p>2011</p></td><td><p>252,483</p></td></tr><tr><td><p>2012</p></td><td><p>259,853</p></td></tr><tr><td><p>2013</p></td><td><p>264,437</p></td></tr><tr><td><p>2014</p></td><td><p>271,662</p></td></tr><tr><td><p>2015</p></td><td><p>279,887</p></td></tr><tr><td><p>2016</p></td><td><p>285,894</p></td></tr><tr><td><p>2017</p></td><td><p>295,133</p></td></tr><tr><td><p>2018</p></td><td><p>308,058</p></td></tr><tr><td><p>Total</p></td><td><p>2,459,803</p></td></tr></tbody></table><p> </p><p>NHS England holds data in relation to specialised commissioning spend that will contribute to the overall spend, from 2013/14 onwards. The financial values have been consolidated through the use of NPoC (National Programme of Care) codes and are taken from our annual spend analysis exercise. This exercise uses Provider Aggregate Contract Monitoring as the basis for the data; where this data is incomplete hubs will apportion / estimate any missing values. The costs for chemotherapy and specialised cancer surgery have been combined for 2013/14 and 2014/15.</p><table><tbody><tr><td><p> </p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p>NPoC</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>B01 - Radiotherapy</p></td><td><p>340.2</p></td><td><p>315.2</p></td><td><p>368.5</p></td><td><p>425.0</p></td><td><p>390.9</p></td></tr><tr><td><p>B02 - Chemotherapy</p></td><td rowspan="2"><p>1,730.8</p></td><td rowspan="2"><p>2,305.9</p></td><td><p>1,417.1</p></td><td><p>1,858.3</p></td><td><p>2,014.8</p></td></tr><tr><td><p>B03 - Specialised cancer surgery</p></td><td><p>1,071.3</p></td><td><p>806.3</p></td><td><p>1,240.5</p></td></tr><tr><td><p>B04 - Specialised cancer diagnostics</p></td><td><p>56.3</p></td><td><p>66.3</p></td><td><p>78.3</p></td><td><p>78.1</p></td><td><p>98.2</p></td></tr><tr><td><p>B05 - Children and young adult cancer services</p></td><td><p>79.9</p></td><td><p>94.0</p></td><td><p>121.9</p></td><td><p>124.1</p></td><td><p>178.8</p></td></tr><tr><td><p>Total</p></td><td><p>2,207.2</p></td><td><p>2,781.4</p></td><td><p>3,057.1</p></td><td><p>3,291.8</p></td><td><p>3,923.1</p></td></tr></tbody></table><p> </p><p>Additionally, as a further indication toward total spend, NHS Improvement estimates the total cost to National Health Service trusts and NHS foundation trusts for providing oncological treatment as follows.</p><table><tbody><tr><td><p>Year</p></td><td><p>Estimated total cost (£ million)</p></td></tr><tr><td><p>2010-11</p></td><td><p>£1,801</p></td></tr><tr><td><p>2011-12</p></td><td><p>£2,051</p></td></tr><tr><td><p>2012-13</p></td><td><p>£2,259</p></td></tr><tr><td><p>2013-14</p></td><td><p>£2,457</p></td></tr><tr><td><p>2014-15</p></td><td><p>£2,706</p></td></tr><tr><td><p>2015-16</p></td><td><p>£2,864</p></td></tr><tr><td><p>2016-17</p></td><td><p>£2,955</p></td></tr><tr><td><p>2017-18</p></td><td><p>£3,224</p></td></tr></tbody></table><p> </p><p>The data source for the table is from reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients. Cost data provided includes:</p><p>- Those that relate to the following treatment function code (TFC):</p><p>- 260 - Paediatric medical oncology</p><p>- 370 - Medical oncology</p><p>- 503 - Gynaecological oncology</p><p>- 800 - Clinical oncology (previously radiotherapy);</p><p> </p><p>- Cancer multi-disciplinary team meetings;</p><p>- Chemotherapy and radiotherapy services; and</p><p>- Cancer related community health services.</p><p>This may not cover all costs associated with oncology. There are areas related to oncology where the costs cannot be identified. These would include:</p><p>- Homecare drugs;</p><p>- Diagnostic imaging; and</p><p>- Other cancer related health resource groups (HRGs) in other TFCs.</p><p> </p><p>There are no primary care costs included within the data.</p><p>Data on the number of IT systems used within oncology treatment in the NHS is not available.</p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
grouped question UIN
236365 more like this
236367 more like this
question first answered
less than 2019-04-02T11:24:27.077Zmore like thismore than 2019-04-02T11:24:27.077Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon more like this